GLP-1 Agonists: Beyond Weight Loss Applications

The drugs Ozempic, Wegovy, and Mounjaro have dominated headlines for their ability to help people shed significant weight. However, the scientific community is now looking past the scale. Recent clinical trials and emerging data suggest these medications, known as GLP-1 agonists, may act as powerful interventions for cardiovascular disease, chronic kidney issues, and potentially even addiction.

The Cardiovascular Breakthrough

For years, doctors viewed weight loss as the primary mechanism for improving heart health. However, recent findings suggest GLP-1 drugs provide direct cardiovascular benefits independent of weight reduction.

In March 2024, the U.S. Food and Drug Administration (FDA) approved Wegovy (semaglutide) for a specific new indication: reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. This approval was based on the landmark SELECT trial, funded by Novo Nordisk.

Key findings from the SELECT trial included:

  • Participants: The study followed 17,604 adults aged 45 years or older.
  • Results: Patients taking semaglutide saw a 20% reduction in major adverse cardiovascular events (MACE) compared to those on a placebo.
  • Significance: This was the first time a weight-management medication was proven to prevent life-threatening cardiovascular events in a large-scale population without diabetes.

The drug appears to reduce inflammation and lower blood pressure, which contributes to better heart health regardless of how many pounds the patient loses.

Treating Kidney Disease

Chronic kidney disease (CKD) affects millions of people, particularly those with Type 2 diabetes. Until recently, treatment options to stop the progression of kidney failure were limited.

In 2024, the results of the FLOW trial demonstrated such overwhelming success that the trial was stopped early for efficacy. This study focused on patients with Type 2 diabetes and chronic kidney disease treated with semaglutide.

The data showed that participants taking the drug experienced a 24% lower risk of kidney disease progression or death from kidney and cardiovascular causes. Based on these results, experts anticipate that GLP-1 agonists will become a standard pillar of care for preserving kidney function, sitting alongside blood pressure management and glucose control.

The Addiction Connection

Perhaps the most surprising frontier for GLP-1 agonists is the treatment of substance use disorders. While currently anecdotal or in early trial phases, reports from patients have sparked intense scientific interest.

Many users taking Ozempic or Mounjaro for weight loss report a sudden loss of interest in alcohol, nicotine, and even compulsive behaviors like online shopping or nail-biting. This phenomenon quiets what many call “food noise,” but it seems to dampen “addiction noise” as well.

The Science of Cravings: GLP-1 receptors are not just found in the gut; they are also present in the brain’s reward centers. When activated, these receptors may regulate the release of dopamine, the neurotransmitter responsible for pleasure and craving.

  • Animal Studies: Research conducted at the University of Pennsylvania showed that GLP-1 drugs reduced cocaine-seeking behavior in rats. Similar studies have shown reduced alcohol intake in rodents.
  • Human Trials: Several clinical trials are currently recruiting or underway to test this in humans. For example, researchers at the University of North Carolina at Chapel Hill and Oklahoma State University are investigating semaglutide’s effect on alcohol use disorder and smoking cessation.

While the FDA has not yet approved these drugs for addiction, the biological plausibility is strong, leading many addiction specialists to prescribe them off-label in select cases.

Neuroprotection: Parkinson’s and Alzheimer’s

Another promising area of research involves neurodegenerative diseases. Because GLP-1 agonists reduce inflammation throughout the body, researchers believe they may help protect the brain from the damage associated with Alzheimer’s and Parkinson’s disease.

A Phase 2 trial of lixisenatide (an older GLP-1 drug) published in the New England Journal of Medicine in April 2024 showed that the drug slowed the progression of motor symptoms in people with early-stage Parkinson’s disease.

  • The Findings: Over 12 months, patients on the placebo saw their symptoms worsen significantly, while those on the medication saw no worsening of motor symptoms.
  • Side Effects: The study did note higher rates of nausea among the treatment group, consistent with the known side effects of the drug class.

Currently, two large Phase 3 trials (EVOKE and EVOKE Plus) are testing oral semaglutide in thousands of patients with early Alzheimer’s disease. Results are expected within the next two years.

How GLP-1 Agonists Work

To understand why one drug can treat so many different conditions, it helps to look at the mechanism of action. GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the intestines after you eat.

Synthetic versions like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) mimic this hormone but last much longer in the body. They perform three main functions:

  1. Insulin Secretion: They signal the pancreas to release insulin when blood sugar is high.
  2. Gastric Emptying: They slow down how fast the stomach empties, making you feel full longer.
  3. Brain Signaling: They bind to receptors in the hypothalamus to signal satiety (fullness) and reduce the craving for reward-based inputs (food, and potentially drugs or alcohol).

Specific Drugs and Their Current Status

While the science is moving fast, it is important to know which specific brand names are associated with these findings.

  • Semaglutide: Sold as Ozempic (Type 2 Diabetes) and Wegovy (Obesity/Cardiovascular prevention). This is the molecule behind the SELECT and FLOW trials.
  • Tirzepatide: Sold as Mounjaro (Type 2 Diabetes) and Zepbound (Obesity). This acts on both GLP-1 and GIP receptors. Recent studies suggest it may be even more potent for weight loss and sleep apnea improvement.
  • Liraglutide: Sold as Saxenda or Victoza. This requires daily injections rather than weekly.
  • Retatrutide: An experimental “triple agonist” (GLP-1, GIP, and Glucagon) currently in Phase 3 trials, showing promise for liver disease (MASH/NASH) alongside massive weight loss.

Frequently Asked Questions

Can I get Ozempic specifically for alcoholism? Currently, no. The FDA has not approved Ozempic or Wegovy for the treatment of Alcohol Use Disorder. However, some physicians may prescribe it “off-label” if they believe the patient will benefit, though insurance is unlikely to cover it for this specific diagnosis alone.

Do these drugs help with heart failure? Yes. In 2023, studies showed that Wegovy significantly reduced symptoms in people with a specific type of heart failure called HFpEF (heart failure with preserved ejection fraction) in obese patients. It improved their exercise capacity and physical function.

Are there cognitive side effects? While the research into Alzheimer’s is promising, there is no definitive proof yet that these drugs improve memory in healthy adults. The current focus is on preventing decline in those with disease markers.

Will insurance cover these drugs for heart disease? Following the FDA approval of Wegovy for cardiovascular risk reduction in March 2024, Medicare (which is generally barred from covering weight loss drugs) issued guidance allowing coverage of Wegovy specifically for patients with a history of heart disease. Commercial insurers often follow Medicare’s lead, but policies vary by provider.